Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes.
about
Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombinNeuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinaseThe evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activityEpigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicityIntratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cellsThe glial growth factors deficiency and synaptic destabilization hypothesis of schizophreniaAt the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of boneSolution structure of epiregulin and the effect of its C-terminal domain for receptor binding affinityBiomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cellsFactor Xa induces mitogenesis of vascular smooth muscle cells via autocrine production of epiregulinGenes that mediate breast cancer metastasis to lungSrc family kinases and HER2 interactions in human breast cancer cell growth and survival.Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage.Molecular characterization of lung dysplasia induced by c-Raf-1.Structure and function of epigen, the last EGFR ligand.Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.Glial-neuronal interactions in the neuroendocrine control of mammalian puberty: facilitatory effects of gonadal steroids.Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops.Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.Contribution of glial-neuronal interactions to the neuroendocrine control of female puberty.High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor.The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines.Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.Stretch-induced fetal type II cell differentiation is mediated via ErbB1-ErbB4 interactions.Polymorphism in epidermal growth factor is related to clinical outcomes of metastatic colorectal cancer patients treated with cetuximab: a systematic review and meta-analysis.Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas.Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptorEpiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage.Epiregulin as a therapeutic target in non-small-cell lung cancerErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.Epiregulin: roles in normal physiology and cancerEpiregulin induces human SK-N-BE cell differentiation through ERK1/2 signaling pathway.Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERKToll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury.
P2860
Q22001441-CC842265-3408-4CDD-8ABA-D33B1F4B103AQ22009917-B748A32A-A9E3-4DBD-96A4-09D8E202261BQ24314999-EBDACCBB-C2D2-412C-8742-48E0DC234C46Q24324102-DD86838D-933E-4702-B0EF-491510777F6AQ24603941-C80F3660-B4F1-4765-A719-671F2DECFDF8Q24798030-C5821C6B-211F-4216-BDDD-3E95B49DF714Q26866067-B670B72B-B18F-44A0-9288-383811286CB4Q27642394-DE5BC2DF-7A67-45F3-B24E-9413779D6AABQ27852062-D7AC218F-F86E-42C7-B0AF-9D64CE75C25CQ27853346-D6DA26D9-AFB1-4CCE-8BC5-7043DC406DE7Q28564324-E50CADE1-3588-438C-A5FD-F38BA2F00ADEQ28566266-BE2DF29C-052D-4BAA-AE7D-8B7ECB2A7308Q29547479-D5508176-F750-44F2-9A2A-4C7BED04AB33Q30307291-6B145D4F-94F1-42FF-8750-6E3917D89B89Q31111797-5A404315-75B6-42A7-83B4-88B791450A99Q33468458-DB80B917-4EB4-4E61-945A-008DED731704Q33680363-06B54989-0DD0-4CC2-B60F-3485A2ED34CDQ33682988-8CF2B97D-9188-45F3-96DC-6832AEEC2FEDQ33714949-E4811367-1581-42B8-B3F4-3553CE73F270Q33769820-5260BFD2-04CC-4D63-BA23-221868924D3CQ33801908-84C0AC3C-33FE-4F1A-925F-7D34061B03FBQ33968565-6FD0DF12-CBB3-4B64-92C1-1D63967D24E2Q34678739-F4511D55-06A7-413D-84A5-186C0CF54DF1Q35065342-2848E07D-4208-470E-9067-823EDB3CF3E8Q35357793-304D31C0-E39F-4748-900F-1B2E1A0D61FFQ35671281-4C4EAD82-0CE3-4C8F-A2E2-ACDAF649ECC7Q35784682-3B1724A4-9C3E-4605-87FE-9C835A1EFFB7Q36002952-7DED34A1-466D-4CEB-B663-479B6C3A0F58Q36046346-28582422-FC3C-4BCC-8A42-E49592CAD357Q36283930-0DCA98A4-22DF-4233-8170-943931B21B4BQ36334739-F240420C-7796-4F63-AD69-33E42B0E4572Q36677496-6BF22E7E-8EE7-47A7-A125-DB99ACED0E08Q37105016-0FC4E5AD-D576-42D7-86E2-DA124BEF2D2FQ37527393-3DBA3678-E27E-45D3-ABEE-34DDE5AFE7AAQ37566850-1035E711-1F68-4F50-AB52-8B0DF82638E7Q37970020-D716DB3B-E09E-4856-AA80-3739CD0E3258Q38196137-1E5D7030-F5EE-4C2B-BF74-3DA3BB7948C8Q39144096-BBE5B76A-03FC-4C8B-BFAB-CEB897F2A719Q39172441-BF18D8E0-5DF4-49E4-9598-AFD1593D423AQ39700792-E71BE8CB-A2D6-410B-9AA2-A2C3F62558F5
P2860
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Epiregulin is a potent pan-Erb ...... erodimeric receptor complexes.
@en
type
label
Epiregulin is a potent pan-Erb ...... erodimeric receptor complexes.
@en
prefLabel
Epiregulin is a potent pan-Erb ...... erodimeric receptor complexes.
@en
P2093
P2860
P356
P1476
Epiregulin is a potent pan-Erb ...... erodimeric receptor complexes.
@en
P2093
Alimandi M
Andrews GC
Guarino BC
Pinkas-Kramarski R
P2860
P304
10496-10505
P356
10.1074/JBC.273.17.10496
P407
P577
1998-04-01T00:00:00Z